Study outcomes
SECONDARY
The primary outcome in this secondary analysis was the difference in total consumption of standard glasses of alcohol per week after 12 weeks of treatment with dulaglutide compared to placebo. Secondary outcomes were correlation between changes in consumption of alcohol and smoking status at week 12, differences in smoking abstinence rates at week 12 between baseline alcohol drinkers and nondrinkers, number and characteristics of participants who started consuming alcohol from baseline to week 12, and changes in consumption of other drugs (i.e., cannabis, benzodiazepines, opiates, psychostimulants, and others).